Kazim A. Aliev

Kazim A. Aliev

Auto-generated profile, based on publicly available information

Kazim A. Aliev

V.I. Vernadsky Crimean Federal University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
PDF file
VОV. V. Оlекsеnко
V. V. Оlекsеnко
SES. V. Efetov
S. V. Efetov
VZV. A. Zakharov
V. A. Zakharov
KAK. A. Aliyev
K. A. Aliyev
DAD. M. Al-Nsour
D. M. Al-Nsour
Medical article медицинская статья

14 December 2023 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
EZEvgeniya Zyablitskaya
Evgeniya Zyablitskaya
AKA. V. Kubyshkin
A. V. Kubyshkin
LSL. E. Sorokina
L. E. Sorokina
ASA. V. Serebryakova
A. V. Serebryakova
KAK. A. Aliev
K. A. Aliev
ЕЗЕ. Ю. Зяблицкая
Е. Ю. Зяблицкая
The dynamic relationships between tumor cells and their microenvironment are of crucial importance in the development and progression of the malignant process. Given the multifunctional potential of heterogeneous populations surrounding a tumor, targeting components of the microenvironment has long been regarded as a promising strategy in modern anticancer therapy. This review discusses the role of the components of the cellular microenvironment in carcinogenesis, analyzes in detail the main ways and mechanisms of action on the main cell populations, which are of the greatest interest in the context of the development of innovative anticancer therapy.

21 December 2021 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
DVDmitry Igorevich Vodolazhsky
Dmitry Igorevich Vodolazhsky
AMA. V. Mayakovskaya
A. V. Mayakovskaya
Anatolii V KubyshkinAnatolii V Kubyshkin
Anatolii V Kubyshkin
KAK. A. Aliev
K. A. Aliev
IFI. I. Fomochkina
I. I. Fomochkina
The review presents classical and modern views on the molecular genetic causes underlying hereditary predisposition to breast and ovarian cancer. A computerized literature search was carried out in the electronic databases MEDLINE, Scopus, and Web of Science, published between January 1994 and May 2021, using the keywords: «hereditary breast and ovarian cancer», «BRCA» and «DNA repair». Current views on the role of germline mutations in genes for susceptibility to breast cancer (BC): BRCA1, BRCA2, PALB2, TP53, CHEK2, PTEN, ATM, and PPM1D are presented. The role of a complex of genes involved in homologous DNA repair and causing other hereditary oncological diseases is considered. The role of the loss of heterozygosity in these genes, which increases the level of chromosomal instability and leads to an increased risk of malignant transformation, is considered. Germinal mutations in the genes under consideration in 90% of clinical cases are the cause of initiation of tissue malignancy and greatly increase the risk of developing hereditary breast cancer and OC. The review emphasizes the complex nature of pathogenesis and significant polymorphism of genetic targets for hereditary breast cancer and OC. It is concluded that it is necessary to use NGS panels for complex screening of genes of hereditary susceptibility to these oncological diseases. The review provides data on the clinical significance of each group of genes of hereditary predisposition in the pathogenesis of breast cancer and OC, and also demonstrates the possible role of methylation of the promoter regions of genes and the state of mitochondrial DNA in the development of these pathologies. The purpose of this review was to broaden the horizons of specialists in the field of oncology and clinical diagnostics in the context of the rapidly expanding spectrum of molecular genetic markers of hereditary breast and ovarian cancers.

19 February 2024 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
OKO. R. Khabarov
O. R. Khabarov
BSB. D. Seferov
B. D. Seferov
KAK. A. Aliev
K. A. Aliev
DZD. V. Zima
D. V. Zima
EGE. P. Golubinskaya
E. P. Golubinskaya
ЕЗЕ. Ю. Зяблицкая
Е. Ю. Зяблицкая
Purpose of the study. Is to describe the experience of creating a collection of biological images of tumor tissues and biomaterials, which are control samples, for scientific research in morphology and molecular oncology.Materials and methods. We studied the molecular markers of cell cycle regulation, apoptosis, oncogenesis and angiogenesis, the expression of proteins that regulate inflammation and tumor infiltrate cells in biocollections of verified tumors of common localizations: e. g. thyroid cancer, colorectal cancer, breast cancer, prostate adenocarcinoma, endometrioid adenocarcinoma. Also, tissue fragments with normal structure or non-tumor pathology (autoimmune thyroiditis, adenomatous and thyrotoxic goiter, benign formations of the colon, fibrocystic disease of the mammary glands, benign prostatic hyperplasia, endometrial hyperplasia) were used as control samples or comparison groups. The total number of tissue samples is n = 7000.Results. It is reasonable to gather the collection in a pathomorphological laboratory according to the profile of the medical institutions, which has a sufficient volume of incoming target material and specialized morphologists to verify tumors of a given localization. It is necessary to consider the regional and ethnic specifics of the population, which determines the sampling and mutational load. The laboratory must initiate an addition to the informed consent of patients about the possibility of conducting morphological and molecular genetic studies for scientific purposes and publishing their results in a depersonalized form for the development of new elaborations, when signing the contracts with legal entities and individuals and when serving patients within an institution. When working with biocollections, it has to consider having registers of tissue biomaterials of target disorder groups of main localizations with downloading by year from an accessible information system, consider external factors affecting the database (changes in clinical recommendations and classifications, the population of patients served, pandemics and other significant events). The standard of the preanalytical stage, data collection, development of protocols for analytical molecular genetic studies and their evaluation, the utilization of the capabilities of working with reagents for scientific tasks and modeling experiments on laboratory animals are crucial.Conclusion. The formed biocollection made it possible to carry out a number of initiative and funded domestic and international scientific projects at the request of clinicians and fundamental researchers, as well as to improve the quality standards of morphological and molecular genetic oncology diagnostics. Biobanking makes the pathological archive more accessible for review and use, significantly expanding its scientific and practical potential. Scientific and medical research do not conflict and can be used within the same laboratory.

15 September 2024 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
KAK. A. Aliev
K. A. Aliev
EZEvgeniya Zyablitskaya
Evgeniya Zyablitskaya
TMTatyana Makalish
Tatyana Makalish
LSL. E. Sorokina
L. E. Sorokina
EAE. R. Asanova
E. R. Asanova
ЕЗЕ. Ю. Зяблицкая
Е. Ю. Зяблицкая
Aim. Тo study the molecular genetic characteristics of the tumor microenvironment and the mechanisms of cell death in resistant locally advanced breast cancer.Materials and methods. The study included 48 patients with breast cancer T2–4N0–3M0–1 (mean age 55.6 ± 9.8 years), and 29 patients of comparable age with breast fibroadenoma. According to the design of the study, patients were divided into groups: Group 1 included women with breast cancer resistant to neoadjuvant chemotherapy (n = 23), Group 2 – with breast cancer and a complete response to neoadjuvant chemotherapy (n = 25), control Group – with fibroadenoma (n = 29). The expression of markers CD4+, CD8+, CD20+, CD68+, tumor necrosis factor α (TNF-α), vascular endothelial growth factor A (VEGF A), Ang-2, matrix metalloproteinase 12 (MMP-12), inducible nitric oxide synthase (iNOS), bcl-2, p53, CD95 was assessed using immunohistochemistry.Results. When phenotyping immune cells, the following differences were obtained: in the tumor tissue of patients in Group 1, a significant decrease in the number of cytotoxic CD8+ cells was noted compared to Group 2 (p = 0.001) and control (p = 0.032). In Group 2, a significant increase in the number of CD68+ cells was revealed in relation to Group 1 (p = 0.027). The cytokine profile of the tumor microenvironment in Group 1 is characterized by statistically significant overexpression of TNF-α compared to Group 2 (p 0.001) and the control Group (p = 0.01). With regard to apoptotic factors, noteworthy is the significant decrease in the expression of bcl-2 and p53 in Group 1 compared to Group 2 (p = 0.001 and p = 0.02 accordingly).Conclusion. The presented results can serve as the basis for the creation of diagnostic algorithms that have predictive value regarding the effectiveness of NCT, and also to help identify new targets to justify the use of combined breast cancer treatments in the early stage.

21 April 2017 in Clinical Medicine (Russian Journal)
Verified
Journal Article
Open access
DSDenis V. Shaduro
Denis V. Shaduro
VBV. A. Beloglazov
V. A. Beloglazov
APA. V. Petrov
A. V. Petrov
KAK. A. Aliev
K. A. Aliev
Systemic lupus erythematosus (SLE) is a severe rheumatic disease characterized by polysymptomatic clinical picture. At the present stage, there are no updated epidemiological data due to the low prevalence of the disease. The aim of the study was to examine the current clinical and epidemiological characteristics of patients with systemic lupus erythematosus based on the information contained in the territorial register, analysis of occurrence and symptoms at the early stage of the disease. This study demonstrated the epidemiological and clinical characteristics of SLE from the analysis of 107 cases during the period from 2011 to 2013 and retrospective analysis of the cases for 1980-2013. The epidemiological situation was evaluated based on extensive and intensive indicators using statistical software license. The current SLE prevalence was estimated at 5,59 per 100 000 population in 2013, the incidence between 1994 and 2003 at 0,29 per 100 000 population and between 2004 and 2013 at 0,49, with the peak in 2010 up to 1,35 per 100 000 population. The average absolute growth and growth rate of SLE in the first decade was 0,05% and 0,24%, in the second decade 0,001% and 0,006% respectively, with the female to male ratio being 9:1, mean age of the patients 37,62±11,65 years), and ethnic composition of 87 Slavs and 15 Crimean Tatars. The most common symptoms at the early (polyarthritis, fever, dermatitis) and advanced (polyarthritis, Raynaud's syndrome, carditis, myalgia) stages differed from those specified by American College of Rheumatology (1997). The difference between early and late symptoms of SLE was documented . Based on the data obtained, the division of the disease into clinical subtypes (phenotypes) is proposed.